Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Cortical tubers in patients with tuberous sclerosis complex (TSC) are highly associated with intractable epilepsy. Recent evidence suggests a close relationship between FGF13 and seizures. To understand the role of FGF13 in the pathogenesis of cortical tubers, we investigated the expression pattern of FGF13 in cortical tubers of TSC compared with normal control cortices (CTX). We found that both the mRNA and protein levels of FGF13 were significantly higher in the cortical tubers from patients with TSC than in the control cortices. The immunohistochemical results showed strong FGF13 immunoreactivity in abnormal cells, including dysplastic neurons (DNs) and giant cells (GCs). Moreover, double-label immunofluorescence analyses confirmed that FGF13 was mainly localized in neurons and nearly absent in glia-like cells. The protein levels of FGF13 in the TSC samples were positively correlated with the frequency of seizures before surgery. Taken together, these results suggest that the overexpression and distribution pattern of FGF13 may be related to intractable epilepsy caused by TSC.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.neulet.2021.135714 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Cannabidiol Lacks Direct Effect on Cortical Excitability: A Randomized, Double Blind, Placebo Controlled, 3-Way Crossover Trial.
Clin Pharmacol Ther
August 2025
Centre for Human Drug Research, Leiden, The Netherlands.
Cannabidiol (CBD) is approved as an adjunctive treatment of seizures associated with Dravet syndrome, Lennox-Gastaut Syndrome, and tuberous sclerosis. Its therapeutic and adverse effects are thought to arise, at least partly, from a pharmacokinetic interaction with clobazam, another anti-seizure medication (ASM). The goal of this study was to evaluate the intrinsic anti-epileptic and sedative properties of CBD.
View Article and Find Full Text PDFAn interpretable machine learning approach for predicting drug-resistant epilepsy in children with tuberous sclerosis complex.
Front Neurol
August 2025
Department of Pediatrics, Peking University People's Hospital, Beijing, China.
Background: This study developed and validated an interpretable machine learning (ML) algorithm for predicting the risk of drug-resistant epilepsy (DRE) in children with Tuberous sclerosis (TSC).
Methods: To estimate the risk of DRE in pediatric TSC patients, an interpretable ML model was developed and validated. Clinical data were retrospectively collected from 88 pediatric patients with TSC-related epilepsy.
A child with tuberous sclerosis having Novel NRAS gene mutation.
J Family Med Prim Care
July 2025
Department of Pediatrics, Pandit Bhagwat Dayal Sharma Post Graduate Institute of Medical Sciences, Rohtak, Haryana, India.
Tuberous sclerosis (TS) is a rare genetic disorder of autosomal-dominant inheritance. Mutations on either of the two genes Tuberous Sclerosis Complex 1 (TSC1) or Tuberous Sclerosis Complex 2 (TSC2) will lead to hamartomas formation involving many organs, such as the brain, heart, kidneys, skin, lungs, and liver. This case report is about an 11-month-old boy with epilepsy and hypomelanotic macules.
View Article and Find Full Text PDFThe Activation of the Microglial NLRP3 Inflammasome Is Involved in Tuberous Sclerosis Complex-Related Neuroinflammation.
Int J Mol Sci
July 2025
National Clinical Research Center for Child Health and Disorders, Chongqing 400014, China.
Tuberous sclerosis complex (TSC) is a systemic disease caused by mutations in either the TSC1 (encoding hamartin) or TSC2 (encoding tuberin) gene, with mutations in the TSC2 gene potentially leading to more severe clinical symptoms. Neurological symptoms are a common clinical manifestation of TSC, and neuroinflammation is thought to play an important role. Glial cells are a major source of neuroinflammation, but whether microglia are involved in the activation of the NOD-like receptor protein 3 (NLRP3) inflammasome and the expression of interleukin-1β (IL-1β) in TSC patients remains unclear.
View Article and Find Full Text PDFBackground: In the fifteen years since the first patient with drug-resistant epilepsy was treated by MR - guided laser interstitial thermal therapy (LITT) it has revolutionized the surgical treatment of epilepsy. Therapeutic targets have ranged from every form of epileptogenic lesion, including mesial temporal sclerosis (MTS), hypothalamic hamartomas (HH), malformations of cortical development, low-grade epilepsy associated tumors, and cerebral cavernous malformations (CCM), to MRI-normal epileptogenic zones characterized by stereo-electroencephalography (SEEG), to disconnection surgeries such as corpus callosotomy and even functional hemispherotomy. Many series now support the general effectiveness and safety of LITT for epilepsy although we are still in the period where increasing experience and technical advances are driving refinement in the therapy.
View Article and Find Full Text PDF